Rehabilitation of Lance-Adams Syndrome: A Case Report
DOI:
https://doi.org/10.25759/spmfr.341Keywords:
Mioclonia/reabilitaçãoAbstract
Lance-Adams syndrome, or chronic posthypoxic myoclonus, is a rare complication of successful cardiopulmonary resuscitation often associated with cerebellar ataxia. The authors report a 41-year-old patient who presented with clinical features of dysarthria, tetraplegia, severe myoclonus, dysdiadochokinesia and cerebellar ataxia after respiratory arrest in the context of chemotherapy treatment. These symptoms resulted in marked functional consequences with inability to stand or perform activities of daily living. Hypoxic encephalopathy with Lance-Adams syndrome was assumed. Implementation of pharmacological treatment coupled with an intensive interdisciplinary rehabilitation program produced marked symptomatic and functional improvements which permitted autonomous activities of daily living and supervised locomotion after 7 months. The aim of this report was to emphasize the importance of the correct diagnosis and proper management of Lance-Adams syndrome leading to the improvement of the patients’ functional outcomes.
Downloads
References
English WA, Giffin NJ, Nolan JP. Myoclonus after cardiac arrest: pitfalls in diagnosis and prognosis. Anaesthesia. 2009;64:908-11.
Freund B, Sutter R, Kaplan P. Lance-Adams syndrome in the pretargeted temperature management era: a case report and systematic review. Clin EEG Neurosci. 2017;48:130-8.
Gupta HV, Caviness JN. Post-hypoxic Myoclonus: Current Concepts, Neurophysiology, and Treatment. Tremor Other Hyperkinet Mov. 2016;6:409.
Zhang YX, Liu JR, Jiang B, Liu HQ, Ding MP, Song SJ, et al. Lance-Adams syndrome: a report of two cases. J Zhejiang Univ Sci B. 2007;8:715-20.
Hauw JJ, Escourolle R, Baulac M, Morel-Maroger A, Goulon M, Castaigne P. Postmortem studies on posthypoxic and post-methyl bromide intoxication: case reports. Adv Neurol. 1986;43:201–4.
Frucht S, Fahn S. The clinical spectrum of posthypoxic myoclonus. Mov Disord. 2000;15(Suppl 1):2-7.
Obrenovitch TP. Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev. 2008;88:211–47.
Budhram A, Lipson D, Nesathurai S, Harvey D, Rathbone MP. Postanoxic myoclonus: two case presentations and review of medical management. Arch Phys Med Rehabil. 2014;95:588–90. doi: 10.1016/j.apmr.2013.09.008.
Matsumoto RR, Truong DD, Nguyen KD, Dang AT, Hoang TT, Vo PQ, et al. Involvement of GABA(A) receptors in myoclonus. Mov Disord. 2000;15(Suppl 1):47-52.
Welsh JP, Yuen G, Placantonakis DG, Vu TQ, Haiss F, O’Hearn E, et al. Why do Purkinje cells die so easily after global brain ischemia? Aldolase C, EAAT4, and the cerebellar contribution to posthypoxic myoclonus. Adv Neurol. 2002;89:331–59.
Polesin A, Stern M. Post-anoxic myoclonus: a case presentation and review of management in the rehabilitation setting. Brain Inj. 2006;20:213-7.
Lee HL, Lee JK. Lance-Adams syndrome. Ann Rehabil Med. 2011;35:939-43.
Frucht SJ, Trost M, Ma Y, Eidelberg D. The metabolic topography of posthypoxic myoclonus. Neurology. 2004;62:1879-81.
Hiramatsu N, Shime N, Kageyama K, Ashida H, Itoi T, Tanaka Y. Intention myoclonus in paediatric patients following severe cardiopulmonary failure: a report of three cases. Crit Care Resusc. 2002;4:104–6.
Elmer J, Rittenberger JC, Faro J, Molyneaux BJ, Popescu A, Callaway CW, et al. Clinically distinct electroencephalographic phenotypes of early myoclonus after cardiac arrest. Ann Neurol. 2016;80:175-84. doi: 10.1002/ana.24697.
De Léan J, Richardson JC, Hornykiewicz O. Beneficial effects of serotonin precursors in postanoxic action myoclonus. Neurology. 1976;26:863–8.
Rollinson RD, Gilligan BS. Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate. Arch Neurol. 1979;36:44–5.
Goldberg MA, Dorman JD. Intention myoclonus: successful treatment with clonazepam. Neurology. 1976;26:24–6.
Jenner P, Pratt JA, Marsden CD. Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. Adv Neurol. 1986;43:629–43.
Frucht SJ, Louis ED, Chuang C, Fahn S.. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology. 2001;57:1112-4.
Lim LL, Ahmed A. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord. 2005;11:135-7.
Asahi T, Kashiwazaki D, Dougu N, Oyama G, Takashima S, Tanaka K, et al. Alleviation of myoclonus after bilateral pallidal deep brain stimulation for Lance-Adams syndrome. J Neurol. 2015;262:1581–3. doi: 10.1007/s00415-015-7748-x.
Yamada K, Sakurama T, Soyama N, Kuratsu J. Gpi pallidal stimulation for Lance-Adams syndrome. Neurology. 2011;76:1270–2.
Birthi P, Walters C, Ortiz Vargas O, Karandikar N. The use of intrathecal baclofen therapy for myoclonus in a patient with Lance Adams syndrome. PM R. 2011;3:671–3. doi: 10.1016/j.pmrj.2010.12.023.
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright statement
Authors must also submit a copyright statement (as seen below) on article submission.
To the Editor-in-chief of the SPMFR Journal:
The below signed author(s) hereby state that the article
________________________________________ (ref. MFR_________) is
an original unpublished work and all facts stated are a product of the author(s) investigation. This article does not violate any copyright laws or privacy statements. The author(s) also hereby confirm that there is no conflict of interest's issues in this article.
By submitting this article the author(s) agree that after publication all copyrights belong to the SPMFR Journal.
Signed by all authors
Date:
Names (capital letters):
Signatures:
The SPMFR Journal’s contents are follow a Creative Commons licence. After publication the authors can hand out the articles as long as the SPMFR Journal is credited.
